Magnetic materials are known for use in producing hyperthermia in tumors. Fe2O3 nanoparticles, when injected into lymph nodes, have been shown to produce a temperature rise of 14°C in an alternating magnetic. Polymer-coated superparamagnetic iron oxide (SPIO) nanoparticles have also been used to localize the hyperthermia to a tumor by tagging the nanoparticles with an antibody. In addition to the need for biocompatibility when used clinically, it is desirable to view the location of the nanoparticles in vivo prior to initiating treatment both to ensure productive therapy and to avoid normal tissue toxicity.
Dartmouth researchers have now generated a novel nanoparticle composed of a metallic core and a metal oxide shell, which can be used in hyperthermia applications and provide MRI contrast for determining the localization of the nanoparticle. These nanoparticles have large specific absorption rate (SAR) values thereby minimizing the dose of nanoparticles required for hyperthermia treatment. Moreover, in the presence of micro-emulsions, smaller, single domain particles (10-15 nm) with a narrow size distribution are obtained with a maximum SAR of 345 W/g at an alternating field of 150Oe and 250 kHz. As such, these nanoparticles are useful in hyperthermia treatment of cancer and imaging cancer as well as in cell separation techniques.
This technology is claimed in the published United States Patent Application No. 12/522,938 and in a Continuation application. We are seeking an industrial partner interested in its commercialization. (Ref: J403)
Last Updated: 7/24/12